Allergy Therapeutics (LON:AGY) Stock Price Down 5.3% – Time to Sell?

Shares of Allergy Therapeutics plc (LON:AGY) dropped 5.3% on Tuesday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 7.10 ($0.10). Approximately 162,276 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 408,738 shares. The stock had previously closed at GBX 7.50 ($0.10).

Allergy Therapeutics Stock Performance

The company has a 50-day moving average price of GBX 6.73 and a two-hundred day moving average price of GBX 6.59. The company has a current ratio of 1.63, a quick ratio of 1.48 and a debt-to-equity ratio of 835.48. The stock has a market capitalization of £329.31 million, a P/E ratio of -6.46, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics (LON:AGY) last issued its earnings results on Monday, March 31st. The company reported GBX (0.23) ($0.00) EPS for the quarter. Allergy Therapeutics had a negative net margin of 72.86% and a negative return on equity of 266.59%. On average, equities analysts forecast that Allergy Therapeutics plc will post -2.56 earnings per share for the current year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.